Pemvidutide Weight Loss: What the Trials Show So Far
Pemvidutide is still being studied for weight loss. Among approved GLP-1s, the top average loss in a main trial is 20.9%, on tirzepatide 15 mg weekly in SURMOUNT-1.
Weight loss and half-life at a glance
Each FDA label gives half-life in days in section 12.3. This is how long the body takes to clear half a dose.
Percentage of body weight Each result should be read against the placebo from that trial on its page, because trials, doses, and lengths differ.
Trial results for approved options
At present, pemvidutide may be prescribed only as part of a trial. Alongside their main weight trials, these approved medicines can:
| Trial | Dose group | Average weight lost | Placebo or comparison | Weeks | Who was in it |
|---|---|---|---|---|---|
| STEP 1 | Semaglutide 2.4 mg weekly | 14.9% | 2.4% | 68 | Adults with obesity or overweight, without diabetes |
| OASIS 4 | Wegovy pill 25 mg daily | 13.6% | 2.4% | 64 | Adults with obesity or overweight, without diabetes |
| SURMOUNT-1 | Tirzepatide 15 mg weekly | 20.9% | 3.1% | 72 | Adults with obesity or overweight, without diabetes |
| SURMOUNT-2 | Tirzepatide 15 mg weekly | 14.7% | 3.2% | 72 | Adults who have obesity or overweight and type 2 diabetes |
| SCALE Obesity and Prediabetes | Liraglutide 3.0 mg daily | 7.4% | 3% | 56 | Adults who have obesity or are overweight, without type 2 diabetes |
| ATTAIN-1 | Foundayo 17.2 mg daily | 11.1% | 2.1% | 72 | Adults with obesity or overweight, without diabetes |
| ATTAIN-2 | Foundayo 17.2 mg daily | 9.6% | 2.5% | 72 | Adults who have obesity or overweight and type 2 diabetes |
| STEP 2 | Semaglutide 2.4 mg weekly | 9.6% | 3.4% | 68 | Adults who have obesity or overweight and type 2 diabetes |
Listed sources: STEP 1 (FDA label (DailyMed)), SURMOUNT-1 (FDA label (DailyMed)), SURMOUNT-2 (PubMed), SCALE Obesity and Prediabetes (FDA label (DailyMed)), ATTAIN-1 (FDA label (DailyMed)), STEP 2 (PubMed)